IMMUNIC THERAPEUTICS
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option f... or multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
IMMUNIC THERAPEUTICS
Industry:
Biotechnology Life Science Medical Therapeutics
Founded:
2016-04-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.imux.com
Total Employee:
11+
Status:
Active
Contact:
+4989208047700
Total Funding:
224.36 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Person Schema CKEditor Comodo SSL
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Checkmate Pharmaceuticals
Checkmate Pharma is a clinical stage biopharmaceutical company developing a new approach for cancer immunotherapy.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Advisors List
Board_member
2019-04-01
Board_member
2019-01-01
Current Employees Featured
Hella Kohlhof Chief Scientific Officer @ Immunic Therapeutics
Chief Scientific Officer
2017-01-01
Daniel Vitt CEO, President and Director @ Immunic Therapeutics
CEO, President and Director
Andreas Muehler Chief Medical Officer @ Immunic Therapeutics
Chief Medical Officer
2016-04-01
Duane Nash Executive Chairman @ Immunic Therapeutics
Executive Chairman
2020-04-01
Darius-Jean Namdjou Head of Regulatory Affairs & Pharmacovigilance @ Immunic Therapeutics
Head of Regulatory Affairs & Pharmacovigilance
2021-08-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-04-12 | Vital Therapies | Vital Therapies acquired by Immunic Therapeutics | N/A |
Investors List
German Federal Ministry of Education and Research (BMBF)
German Federal Ministry of Education and Research (BMBF) investment in Grant - Immunic Therapeutics
Life Sciences Partners
Life Sciences Partners investment in Series A - Immunic Therapeutics
Omega Funds
Omega Funds investment in Series A - Immunic Therapeutics
IBG Risikokapitalfonds II GmbH & Co. KG
IBG Risikokapitalfonds II GmbH & Co. KG investment in Series A - Immunic Therapeutics
Fund+
Fund+ investment in Series A - Immunic Therapeutics
Bayern Kapital
Bayern Kapital investment in Series A - Immunic Therapeutics
LifeCare Partners
LifeCare Partners investment in Series A - Immunic Therapeutics
bmp Ventures
bmp Ventures investment in Series A - Immunic Therapeutics
LifeCare Partners
LifeCare Partners investment in Series A - Immunic Therapeutics
LSP BioVentures
LSP BioVentures investment in Series A - Immunic Therapeutics
Official Site Inspections
http://www.imux.com Semrush global rank: 2.83 M Semrush visits lastest month: 5.72 K
- Host name: h3013233.stratoserver.net
- IP address: 81.169.244.208
- Location: Berlin Germany
- Latitude: 52.5174
- Longitude: 13.3985
- Timezone: Europe/Berlin
- Postal: 12529
More informations about "Immunic Therapeutics"
Immunic, Inc. InvestorRoom - About
Mar 3, 2025 jessica.breu@imux.com. Rx Communications Paula Schwartz Managing Director +1 917 322 2216 immunic@rxir.com. Subscribe. To receive all investor alerts please …See details»
Immunic, Inc. InvestorRoom - Events and Presentations - ir.imux.com
Feb 11, 2025 To schedule a meeting, please contact your Oppenheimer representative or Jessica Breu at: jessica.breu@imux.com. Listen to the Webcast. Immunic, Inc. 1200 Avenue …See details»
Immunic, Inc. (IMUX)
Find the latest Immunic, Inc. (IMUX) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
SEC Filings - Immunic, Inc. InvestorRoom
1200 Avenue of the Americas Suite 200 New York, NY 10036, USA Phone: +1 332 2559811 Email: info@imux.comSee details»
Contact - Immunic Therapeutics
Email: info@imux.com. Google Map; Immunic AG. Lochhamer Schlag 21 82166 Gräfelfing Germany. Phone: +49 89 2080 477 00 Email: info@imux.com. Google Map; Media and …See details»
Immunic, Inc. (IMUX) Company Profile & Facts - Yahoo Finance
See the company profile for Immunic, Inc. (IMUX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Immunic Therapeutics - Crunchbase Company Profile …
Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases.See details»
Pipeline - Immunic Therapeutics
Email: info@imux.com. Immunic AG. Lochhamer Schlag 21 82166 Gräfelfing Germany. Phone: +49 89 2080 477 00 Email: info@imux.com. Contact Us. Help for patients from Ukraine and Lebanon. Допомога пацієнтам з України та …See details»
Publications - Immunic Therapeutics
Feb 25, 2025 17th Congress of ECCO (European Crohn’s and Colitis Organization) Wednesday, February 16, 2022 – Saturday, February 19, 2022. Poster ECCO Congress 2022; ... Email: …See details»
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS …
Feb 26, 2025 Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and …See details»
FAQs - Immunic, Inc. InvestorRoom
Your shares of Immunic, Inc. remained outstanding; however, in connection with the transaction, Immunic, Inc. conducted a reverse stock split at a ratio of 40:1. If you have questions, you can …See details»
Immunic Highlights 2024 Accomplishments and Upcoming …
Jan 7, 2025 Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and …See details»
Analyst Coverage - Immunic, Inc. InvestorRoom
1200 Avenue of the Americas Suite 200 New York, NY 10036, USA Phone: +1 332 2559811 Email: info@imux.comSee details»
Immunic Inc (IMUX) Stock Price Today, Quote, Latest Discussions ...
Track Immunic Inc (IMUX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of …See details»
Immunic Receives Notice of Allowance for Composition-of-Matter …
NEW YORK, March 20, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic …See details»
Immunic Inc (IMUX) Stock Message Board - InvestorsHub
NEW YORK, Oct. 22, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for …See details»
Immunic Receives Notice of Allowance for ... - Immunic Therapeutics
NEW YORK, August 16, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating …See details»
Immunic, Inc. InvestorRoom - Stock Quote
1200 Avenue of the Americas Suite 200 New York, NY 10036, USA Phone: +1 332 2559811 Email: info@imux.comSee details»
News Releases - Immunic, Inc. InvestorRoom
NEW YORK, May 6, 2023 /PRNewswire/ --Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for …See details»